The government just announced the price Medicare pays for the diabetes-slash-weight loss drug Ozempic will soon be negotiated lower as part of a new program designed to bring down prices. One of 15 drugs now subject to price changes to […]
An update to our reporting on two recently-approved Alzheimer’s drugs: aducanumab and Lecanemab. FDA advisers and many independent watchdogs said there’s no good evidence the hugely expensive shots make a meaningful difference, and they could cause serious side effects. But
The following information is from Public Citizen. Public Citizen, a nonprofit consumer advocacy organization, is calling for federal officials to investigate troubling practices in recent Alzheimer’s disease drug trials. A New York Times report reveals that participants in trials for two drugs—lecanemab
Patients in Alzheimer’s Drug Trials Not Told About Risks Read More »
The following information is from Public Citizen. WASHINGTON, D.C. — According to a new analysis featured today in JAMA Internal Medicine, privatized Medicare Advantage plans have raised Medicare’s costs by $612 billion since 2007, including $82 billion last year alone. The authors — physicians
Gabapentin has quietly become one of the most widely-prescribed drugs in America, and some say that could spell big trouble.
The following is from Public Citizen. Amylyx Pharmaceuticals said on Thursday that it would withdraw AMX0035 (sodium phenylbutyrate and taurursodiol, sold as Relyvrio) from the market. A large clinical trial recently found that the drug did not provide any benefit to patients
Drug manufacturer Amylyx pulls ALS drug Relyvrio from market, citing lack of efficacy Read More »
An update to our reporting on recently-approved Alzheimer’s drugs. You may recall FDA advisers and many independent watchdogs said there’s no good evidence the hugely expensive shots make a meaningful difference, and they could cause serious side effects. But the
The pharmaceutical industry has long claimed that the government trying to negotiate better prices for Medicare, health are for the elderly, takes away from new drug research and development. But a new report by the watchdog group Public Citizen and Protect our Care reveals
